{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:13:23Z","timestamp":1761959603201,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T00:00:00Z","timestamp":1599955200000},"content-version":"vor","delay-in-days":256,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gusu youth medical talent","award":["3101030342000318"],"award-info":[{"award-number":["3101030342000318"]}]},{"DOI":"10.13039\/501100002949","name":"Jiangsu Province","doi-asserted-by":"publisher","award":["QNRC2016747"],"award-info":[{"award-number":["QNRC2016747"]}],"id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.rmcr.2020.101228","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T03:05:59Z","timestamp":1600225559000},"page":"101228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report"],"prefix":"10.1016","volume":"31","author":[{"given":"Shuang","family":"Bian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-251X","authenticated-orcid":false,"given":"Wei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2020.101228_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2020.101228_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.rmcr.2020.101228_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ctrv.2014.06.010","article-title":"Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions","volume":"40","author":"Peters","year":"2014","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.rmcr.2020.101228_bib4","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.2147\/OTT.S194870","article-title":"Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer","volume":"12","author":"Xu","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.rmcr.2020.101228_bib5","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States food and drug administration drug approval summary: gefitinib (ZD1839; iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.rmcr.2020.101228_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cpdd.337","article-title":"Effect of sustained elevated gastric pH levels on gefitinib exposure","volume":"6","author":"Tang","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.rmcr.2020.101228_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2020.101228_bib8","first-page":"412","article-title":"Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations","volume":"17","author":"Zenke","year":"2016","journal-title":"Clin. Lung Canc."},{"key":"10.1016\/j.rmcr.2020.101228_bib9","first-page":"33","article-title":"Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer","volume":"16","author":"Chu","year":"2015","journal-title":"Clin. Lung Canc."},{"key":"10.1016\/j.rmcr.2020.101228_bib10","doi-asserted-by":"crossref","first-page":"85542","DOI":"10.18632\/oncotarget.13458","article-title":"EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction","volume":"7","author":"Kumarakulasinghe","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.rmcr.2020.101228_bib11","article-title":"Antacid use and de novo brain metastases in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who were treated using first-line first-generation epidermal growth factor receptor tyrosine kinase inhibitors","volume":"11","author":"Chen","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.rmcr.2020.101228_bib12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40262-016-0503-3","article-title":"Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options","volume":"56","author":"van Leeuwen","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.rmcr.2020.101228_bib13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003088-200544110-00004","article-title":"Single-dose clinical pharmacokinetic studies of gefitinib","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.rmcr.2020.101228_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12890-020-01217-4","article-title":"A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin","volume":"20","author":"Bian","year":"2020","journal-title":"BMC Pulm. Med."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007120304421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007120304421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:09:09Z","timestamp":1761959349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007120304421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":14,"alternative-id":["S2213007120304421"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2020.101228","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2020.101228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101228"}}